Robust neutralizing antibody assays are essential for evaluating vaccine-induced immune responses.

This technical note explores the design, validation, and optimization of cell-based neutralizing antibody (NAb) assays used to support vaccine clinical development. Learn best practices for assay development, reporter virus selection, and workflow optimization to generate accurate, reproducible immunogenicity data for studies of all sizes.

Key topics include:

• The role of cell-based neutralizing antibody assays in vaccine clinical trials
• Best practices for assay design, validation, and reporter virus selection
• Strategies for improving assay reproducibility, scalability, and high-throughput performance
• Considerations for optimizing cell culture, critical reagents, and automated workflows

As vaccine development continues to evolve, reliable neutralizing antibody assays remain critical for assessing immune responses and supporting clinical decision-making. Learn how robust assay design and standardized workflows can generate high-quality immunogenicity data throughout clinical development.